Background—Unfractionated heparin has been the primary anticoagulant therapy for
percutaneous coronary intervention for> 20 years. Despite the availability of rapid “point of …

Since the first days of percutaneous coronary interventions (PCI), it has been a common
understanding to treat patients with a combination of antiplatelet and anticoagulant drugs to …

In the development of percutaneous intervention, Dotter first used unfractionated heparin
(UFH) alone when performing peripheral angioplasty. 1 In the 1970s Gruentzig added 1 g of …

Laboratory monitoring of heparin. The anticoagulant effect of heparin is typically monitored
using the activated partial thromboplastin time (aPTT). The aPTT test is sensitive to the …

Objectives: We sought to evaluate, in a double-blind, randomized, prospective study, safety
and efficacy of elective percutaneous coronary intervention (PCI), with pharmacotherapy …

Background Continuous heparin infusion after percutaneous transluminal coronary
angioplasty (PTCA) procedures prolongs the hospital stay and could increase the …

Objective: To evaluate the impact of sheath management on bleeding rates. Background:
The procedural characteristics and anticoagulant regimen determine the frequency of …

The advent of new pharmacotherapies and interventional devices has exponentially
increased the breadth of coronary procedures in a variety of clinical settings. The low …

BACKGROUND: Adjunctive pharmacotherapy during percutaneous coronary intervention
(PCI) has historically consisted of a regimen of antiplatelet agents accompanied by an …

Periprocedural thrombus formation is not only responsible for one of the most serious
complications of percutaneous transluminal coronary angioplasty, acute thrombotic …